目的:为实现从母体腹壁混合信号中提取高信噪比和波形清晰的胎儿心电信号,提出一种融合核主成分分析(kernel principal component analysis,KPCA)、快速独立成分分析(fast independent component analysis,FastICA)及奇异值分解(singula...目的:为实现从母体腹壁混合信号中提取高信噪比和波形清晰的胎儿心电信号,提出一种融合核主成分分析(kernel principal component analysis,KPCA)、快速独立成分分析(fast independent component analysis,FastICA)及奇异值分解(singular value decomposition,SVD)的胎儿心电信号提取算法。方法:首先,采用KPCA对母体心电信号进行降维,再利用改进的基于负熵的FastICA处理降维后的数据,得到独立成分。随后,引入样本熵进行信号通道选择,挑选出包含最多母体信息的信号通道。在选中的母体通道上进行SVD,得到母体心电信号的近似估计,再用腹壁源信号减去该信号得到胎儿心电的初步估计。最后,采用改进的基于负熵的FastICA成功分离出纯净的胎儿心电信号。在腹部和直接胎儿心电图数据库(Abdominal and Direct Fetal Electrocardiogram Database,ADFECGDB)和PhysioNet 2013挑战赛数据库中对提出的算法进行验证。结果:提出的算法在主观视觉效果和客观评价指标上都表现出优越的性能。在ADFECGDB数据库中,胎儿QRS复合波检测的敏感度、阳性预测值和F1值分别为99.74%、98.85%和99.30%;在PhysioNet 2013挑战赛数据库中,胎儿QRS复合波检测的敏感度、阳性预测值和F1值分别为99.10%、97.87%和98.48%。结论:融合KPCA、FastICA及SVD的胎儿心电信号提取算法在提取胎儿心电信号的同时有效处理了附加噪声,为胎儿疾病的早期诊断提供了有力支持。展开更多
Introduction: Ramadan is the ninth lunar month of the Muslim calendar, and fasting during Ramadan is one of the five pillars of Islam. Muslim cancer patients and health professionals are faced with a dilemma between t...Introduction: Ramadan is the ninth lunar month of the Muslim calendar, and fasting during Ramadan is one of the five pillars of Islam. Muslim cancer patients and health professionals are faced with a dilemma between the necessity of fasting and its possible adverse effects during Ramadan on the health status of cancer patients. We believe that addressing the issue of fasting in cancer patients is of global interest. Objectives: Prevalence of fasting in cancer patients during Ramadan;Predictive factors of Ramadan fasting in cancer patients;The effect of fasting during Ramadan on the quality of life of cancer patients. Materials and Methods: A structured questionnaire was used to interview adult cancer patients who received chemotherapy IV—or oral treatment at the medical oncology department at the Hassan II University Hospital in Fez during the month of Ramadan 1443 Hijri (April to May 2022). The quality of cancer patients’ lives during their fasting practice in Ramadan was evaluated via the QLQ-C30 questionnaires. Results: 48% of patients did not fast during Ramadan, 22% and 30% were partial and complete fasters respectively. Patients, with OMS 0 to 1, who receive outpatient treatment, non-metastatic patients and patients on oral treatment were more frequent in the completely fasted group. All these factors showed statistically significant values (p < 0.05). 44% of patients sought advice from the treating oncologist if they could fast, while only 15% of patients during Ramadan asked an imam if they could be excused from fasting. A comparison of the QLQ-C30 data showed a significant improvement in emotional functioning with fasting, however, patients had clinically more but not significantly fatigue after fasting. Conclusion: Female gender, good WHO, non-metastatic disease, and oral or outpatient treatment were more likely to be fasting. This study argues that fasting did not influence the quality of life, and appears to significantly improve emotional functioning in cancer patients during Ramadan.展开更多
In the emerging world of biotech innovation, the fast-to-clinic/market strategy has emerged as a critical “mantra” for biotech, investors, and CDMOs. This approach addresses the escalating costs and complexities of ...In the emerging world of biotech innovation, the fast-to-clinic/market strategy has emerged as a critical “mantra” for biotech, investors, and CDMOs. This approach addresses the escalating costs and complexities of research and development by streamlining the path from concept to clinical trials and, ultimately, to market. The article delves into the intricacies of implementing a fast-to-clinic/market strategy, underlining the empowering role of strategic decision-making in preclinical and commercial stages. The plan advocates for a phase-appropriate approach, where the development decision is tailored to each phase of the product’s lifecycle. This ensures that resources are allocated efficiently, risks are managed effectively, and the product can move through the development pipeline accelerated without compromising quality or regulatory compliance. The article also discusses the role of CDMOs in facilitating rapid product development and the essential factors biotech companies must consider when selecting a partner for outsourcing. These factors include the CDMO’s expertise in navigating regulatory landscapes, technological capabilities, and ability to scale processes efficiently. Moreover, the article stresses the importance of agility and flexibility in the fast-to-clinic/market approach. Biotech companies are encouraged to adopt adaptable strategies that respond to the fast-evolving regulatory and market landscapes.展开更多
文摘目的:为实现从母体腹壁混合信号中提取高信噪比和波形清晰的胎儿心电信号,提出一种融合核主成分分析(kernel principal component analysis,KPCA)、快速独立成分分析(fast independent component analysis,FastICA)及奇异值分解(singular value decomposition,SVD)的胎儿心电信号提取算法。方法:首先,采用KPCA对母体心电信号进行降维,再利用改进的基于负熵的FastICA处理降维后的数据,得到独立成分。随后,引入样本熵进行信号通道选择,挑选出包含最多母体信息的信号通道。在选中的母体通道上进行SVD,得到母体心电信号的近似估计,再用腹壁源信号减去该信号得到胎儿心电的初步估计。最后,采用改进的基于负熵的FastICA成功分离出纯净的胎儿心电信号。在腹部和直接胎儿心电图数据库(Abdominal and Direct Fetal Electrocardiogram Database,ADFECGDB)和PhysioNet 2013挑战赛数据库中对提出的算法进行验证。结果:提出的算法在主观视觉效果和客观评价指标上都表现出优越的性能。在ADFECGDB数据库中,胎儿QRS复合波检测的敏感度、阳性预测值和F1值分别为99.74%、98.85%和99.30%;在PhysioNet 2013挑战赛数据库中,胎儿QRS复合波检测的敏感度、阳性预测值和F1值分别为99.10%、97.87%和98.48%。结论:融合KPCA、FastICA及SVD的胎儿心电信号提取算法在提取胎儿心电信号的同时有效处理了附加噪声,为胎儿疾病的早期诊断提供了有力支持。
文摘Introduction: Ramadan is the ninth lunar month of the Muslim calendar, and fasting during Ramadan is one of the five pillars of Islam. Muslim cancer patients and health professionals are faced with a dilemma between the necessity of fasting and its possible adverse effects during Ramadan on the health status of cancer patients. We believe that addressing the issue of fasting in cancer patients is of global interest. Objectives: Prevalence of fasting in cancer patients during Ramadan;Predictive factors of Ramadan fasting in cancer patients;The effect of fasting during Ramadan on the quality of life of cancer patients. Materials and Methods: A structured questionnaire was used to interview adult cancer patients who received chemotherapy IV—or oral treatment at the medical oncology department at the Hassan II University Hospital in Fez during the month of Ramadan 1443 Hijri (April to May 2022). The quality of cancer patients’ lives during their fasting practice in Ramadan was evaluated via the QLQ-C30 questionnaires. Results: 48% of patients did not fast during Ramadan, 22% and 30% were partial and complete fasters respectively. Patients, with OMS 0 to 1, who receive outpatient treatment, non-metastatic patients and patients on oral treatment were more frequent in the completely fasted group. All these factors showed statistically significant values (p < 0.05). 44% of patients sought advice from the treating oncologist if they could fast, while only 15% of patients during Ramadan asked an imam if they could be excused from fasting. A comparison of the QLQ-C30 data showed a significant improvement in emotional functioning with fasting, however, patients had clinically more but not significantly fatigue after fasting. Conclusion: Female gender, good WHO, non-metastatic disease, and oral or outpatient treatment were more likely to be fasting. This study argues that fasting did not influence the quality of life, and appears to significantly improve emotional functioning in cancer patients during Ramadan.
文摘In the emerging world of biotech innovation, the fast-to-clinic/market strategy has emerged as a critical “mantra” for biotech, investors, and CDMOs. This approach addresses the escalating costs and complexities of research and development by streamlining the path from concept to clinical trials and, ultimately, to market. The article delves into the intricacies of implementing a fast-to-clinic/market strategy, underlining the empowering role of strategic decision-making in preclinical and commercial stages. The plan advocates for a phase-appropriate approach, where the development decision is tailored to each phase of the product’s lifecycle. This ensures that resources are allocated efficiently, risks are managed effectively, and the product can move through the development pipeline accelerated without compromising quality or regulatory compliance. The article also discusses the role of CDMOs in facilitating rapid product development and the essential factors biotech companies must consider when selecting a partner for outsourcing. These factors include the CDMO’s expertise in navigating regulatory landscapes, technological capabilities, and ability to scale processes efficiently. Moreover, the article stresses the importance of agility and flexibility in the fast-to-clinic/market approach. Biotech companies are encouraged to adopt adaptable strategies that respond to the fast-evolving regulatory and market landscapes.